📈 IPO Listing & Market Debut
- IPO Price Band: ₹540–570 per share Screener+11mint+11Moneycontrol+11
- Debut on BSE & NSE: Listed today (July 21, 2025) at ₹723.05–723.10, marking ~27% gain mint+4mint+4The Economic Times+4
- Pre-open Activity: Trades near ₹670 pre-open; grey market premium (GMP) around ₹179 (~31% uplift) Moneycontrol+1mint+1
🏭 Company Overview
Anthem Biosciences is a CRDMO (Contract Research, Development & Manufacturing Organization) excelling in fermentation-based APIs, peptides, oligonucleotides, ADCs, and RNA therapeutics. It operates the largest fermentation capacity in India (182 kL) and serves over 675 clients in 44 countries NSE India+7mint+7Screener+7.
FY25 Highlights:
- Revenue: ₹1,844 Cr (+30% YoY)
- PAT: ₹451 Cr (+23%)
- EBITDA Margin: ~37%, ROCE ~27% The Economic Times+3mint+3Moneycontrol+3mint+1The Economic Times+1
💡 Listing Highlights & Analyst View
- Listing premium was ~27% (₹723 vs IPO ₹570), slightly below grey market levels but still strong Chittorgarh+6mint+6The Economic Times+6.
- QIB Demand: Subscribed ~193×; NIIs ~45×; Retail ~6×, with anchor investor backing of ~₹1,016 Cr mint+3mint+3Upstox – Online Stock and Share Trading+3.
- Analyst Insight: Valuation stands at ~₹31,800–32,800 Cr post-listing. With a P/E of ~65× based on screened data and strong growth fundamentals, it’s seen as premium but captures India’s biotech resurgence ScreenerThe Economic Times.
✅ Should You Buy, Hold, or Book Profits?
- Short-term Traders: Consider partial profit booking, as listing gains approach grey market levels (~31%) Moneycontrol+1Moneycontrol+1.
- Long-term Investors: The company’s strong margins, niche positioning, and sector tailwinds make it a compelling long-term pick in biotech.
🔥 Key Metrics at a Glance
- Share Price (as of open): ₹723
- Market Cap: ~₹32,800 Cr
- P/E Ratio (TTM): ~65×
- Profit & Margins: ₹451 Cr PAT, ~37% EBITDA margin Investing.com+4mint+4The Economic Times+4Investing.com
❓ FAQs
Q1. What price did it list at?
Listed at ~₹723 on NSE/BSE—about 27% above issue price of ₹570 Groww+7mint+7mint+7.
Q2. How much can I gain if I bought at IPO?
Based on current listing price, potential gain is ~27–31%, considering GMP and market debut Moneycontrol.
Q3. Who’s investing?
High demand from QIBs (~193×), NIIs (~45×), and retail (~6×); secured ₹1,016 Cr from anchor investors Moneycontrol+5mint+5Upstox – Online Stock and Share Trading+5.
Q4. Is it valued high?
Listing placed valuation around ₹32K Cr with P/E ~65×, reflecting premium placed on growth and margins in CRDMO sector Upstox – Online Stock and Share Trading+5Screener+5Moneycontrol+5.
Q5. What’s the growth trigger?
Strong focus on fermentation-based APIs, scaling global client base, operating efficiencies, and biotech demand expansion The Economic Times+3mint+3Moneycontrol+3.
💡 Final Take
Anthem Biosciences is off to a solid start, grabbing a ~27% listing premium on strong fundamentals. Fast-paced gains may entice short-term profits, but its high margins, sector niche, and growth trajectory position it well for long-term investors. If you’re bullish on biotech/CRDMO growth, this could be a core addition.
